ENDEAVOR IV trial - Summary & Results
Upcoming SlideShare
Loading in...5
×
 

ENDEAVOR IV trial - Summary & Results

on

  • 494 views

http://www.theheart.org/web_slides/1135907.do

http://www.theheart.org/web_slides/1135907.do

A randomized, single-blind study comparing Zotarolimus and Paclitaxel-Eluting Stents (ENDEAVOR IV) in more than 1500 patients with CAD

Statistics

Views

Total Views
494
Views on SlideShare
494
Embed Views
0

Actions

Likes
0
Downloads
2
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

ENDEAVOR IV trial - Summary & Results ENDEAVOR IV trial - Summary & Results Presentation Transcript

  • ENDEAVOR IV (Randomized Comparisonof Zotarolimus- and Paclitaxel-ElutingStents in Patients With CAD)
  • ENDEAVOR IV (Randomized Comparison of Zotarolimus-and Paclitaxel-Eluting Stents in Patients With CAD)M Leon (Columbia University, New York, NY)Transcatheter Cardiovascular Therapeutics 2007 Meeting• A randomized, single-blind study comparing the Endeavor and Taxus stents in more than 1500 patients• Primary outcome: Target vessel failure: a composite of cardiac death, MI, and target vessel revascularization at nine months
  • ENDEAVOR IV: ResultsENDEAVOR IV: ENDEAVOR IV:Nine- and 12-month results Eight-month angiographic follow-upEnd point Endeavor (%) Taxus (%) p End point Endeavor Taxus p9-mo TVF 6.6 7.2 <0.001* % diameter 26 16 <0.001 stenosis, in-stent12-mo TVF 7.7 9.4 0.267 % diameter 32 26 0.004 stenosis, in-segment9-mo TVR 5.4 4.9 0.728 Late loss, in-stent 0.67 0.42 <0.001 (mm)12-mo TVR 6.3 6.7 0.753 Late loss, 0.36 0.23 0.023 in-segment (mm)• Endeavor stent noninferior to Taxus • In-segment late lumen loss greaterin terms of primary end point for Endeavor stentTVF = target vessel failure; TVR = target vessel revascularization*p for noninferiority
  • ENDEAVOR IV: Commentary*"We think this is an important trial because its the basis for approval of the next[drug-eluting stent] in the United States. I wouldnt necessarily use the worldblockbuster. " - Dr Marty Leon"My concern is whether the failure of Endeavor to meet the noninferioritysecondary end point of in-segment late loss may become even more evident in ahigher-risk patient cohort. . . . But that still remains to be demonstrated." - Dr Patrick Serruys*All comments from Endeavor IV results get mixed reviews: Interventionalists prove a tougher crowdthan FDA panel (http://www.theheart.org/article/820229.do)
  • Become a member of http://www.theheart.org Become a fan on Facebook: http://www.facebook.com/theheartorg Follow us on Twitter: http://www.twitter.com/theheartorgtheheart.org is the leading online source of independent cardiology news.We are the top provider of news and opinions for over 100 000 physicians.